Drugs / BOTOX®:onabotulinumtoxinA (Allergan Co Ltd), commercially available botulinum toxin type A1
BOTOX®:onabotulinumtoxinA (Allergan Co Ltd), commercially available botulinum toxin type A1
also known as
BOTOX
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT01910363 Comparator | Jul 2013 → Jan 2014 | — | University of Tokushima | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BOTOX:onabotulinumtoxinA (Allergan Co Ltd), commercially available botulinum toxin type A1 | “BOTOX®:onabotulinumtoxinA (Allergan Co Ltd), commercially available botulinum toxin type A1” NCT01910363 ↗ |
| Known as | BOTOX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01910363 ↗ |
| Modality | Protein / enzyme biologic | “commercially available botulinum toxin preparation of type A1” NCT01910363 ↗ |
| Route | Intramuscular | “Intramuscular injection of the botulinum toxin preparation” NCT01910363 ↗ |